Abstract
Vaccinations with tumor cells engineered to express certain cytokines have been demonstrated to induce potent and specific antitumor immunity. In our previous report, we carried out a comparative study on the ability of cytokine-gene-modified tumor vaccines to induce host immune responses, and found that irradiated tumor cells, genetically modified to secrete granulocyte/macrophagecolony-stimulating factor (GM-CSF tumor vaccine), were the most potent stimulators of systemic antitumor immunity. In this report, using the experimental tumor models in which the GM-CSF tumor vaccine was less effective in immunopotentiation, we found that the combined use of a biological response modifier (BRM) OK-432 remarkably enhanced the antitumor activity induced by the GM-CSF tumor vaccine. These data indicate the possible role of a BRM such as OK-432 to intensify further the specific tumor vaccination therapy.
Similar content being viewed by others
References
Abe J, Wakimoto H, Nakamura Y, Kanegae Y, Saito I, Aoyagi M, Hirakawa K, Hamada H (1994) Immunogene therapy for cancer by cytokine gene-modified tumor vaccine and tumor-infiltrating lymphocytes (TIL). Cancer Gene Therapy 1: 312
Anderson WF (1994) Gene therapy for cancer. Hum Gene Ther 5: 1
Aoki T, Tashiro K, Miyatake S, Kinashi T, Nakano T, Oda Y, Kikuchi H, Honjo T (1992) Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc Natl Acad Sci USA 89: 3850
Asher AL, Mule JJ, Kasid A, Restifo NP, Solo JC, Reichert CM, Jaffe G, Fendly B, Kriegler M, Rosenberg SA (1991) Murine tumor cells transduced with the gene for tumor necrosis factor-α. J Immunol 146: 3227
Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, McGowan P, Linsley PS (1992) Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecule CD28 and CTLA-4. Cell 71: 1093
Colombo MP, Forni G (1994) Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 15: 48
Division of Comparative Medicine, MIT (1987) Guidelines of Laboratory Animal Care and Use, Massachusettes Institute of Technology
Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and longlasting anti-tumor immunity. Proc Natl Acad Sci USA 90: 3539
Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397
Fidler IJ (1975) Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res 35: 218
Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E (1990) Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 50: 7820
Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E (1990) Interleukin-2 gene transfer into tumor cells abrogate tumorigenicity and induces protective immunity. J Exp Med 172: 1217
Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, Pardoll DM (1991) Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (Washington DC) 254: 713
Hersh EM, Taylor CW (1991) Immunotherapy by active immunization: use of nonspecific stimulants and immunomodulators. In: DeVita VT, Hellman S, Rosenberg SA (eds) Biologic therapy of cancer. Lippincott, Philadelphia, p 613
Hojo H, Hashimoto Y (1981) Cytotoxic cells induced in tumor-bearing rats by aStreptococcus preparation (OK-432). Gann 72: 692
Moriya Y, Sato H, Ito K, Saito M, Yoshida T, Ishida N (1993) Induction of antitumor L3T4-positive T cells by OK-432 at tumor sites in mice. Cancer Immunol Immunother 36: 245
Pardoll DM (1993) Cancer vaccines. Immunol Today 14: 310
Porgador A, Tzehoval E, Katz A, Vadai E, Revel M, Feldman M, Eisenbach L (1992) Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 52: 3679
Porgador A, Bannerji R, Watanabe Y, Feldman M, Gilboa E, Eisenbach L (1993) Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gene-inserted tumor cells. J Immunol 150: 1458
Saito M, Nanjo M, Kataoka M, Moriya Y, Sugawara Y, Yoshida T, Ishida N (1988) Adoptive immunotherapy by pantropic killer cells recovered from OK-432-injected tumor sites in mice. Cancer Res 48: 4163
Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9: 271
Talmadge JE, Herberman RB (1986) The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers. Cancer Treat Rep 70: 171
Tepper RI, Pattengale PK, Leder P (1989) Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57: 503
Townsend SE, Allison JP (1993) Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (Washington DC) 259: 368
Wakimoto H, Abe J, Nakamura Y, Kanegae Y, Saito I, Aoyagi M, Hirakawa K, Hamada H (1994) Enhanced antitumor effects by cytokine gene-modified tumor vaccines and IL-2 secreting cytotoxic T lymphocytes. In: Gene therapy. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, p. 164
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Abe, J., Wakimoto, H., Aoyagi, M. et al. Cytokine-gene-modified tumor vaccination intensified by a streptococcal preparation OK-432. Cancer Immunol Immunother 41, 82–86 (1995). https://doi.org/10.1007/BF01527403
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01527403